What we do

Proactive and hands-on advocacy is a core value for the EAU. Engagement with the EU and regulatory bodies is crucial to address issues related to urology.

Urology Week

Urology Week is an initiative of the European Association of Urology, which brings together national urological societies, urology practitioners, urology nurses, the patients and their families, and politicians with the aim to increase awareness of urological conditions among the general public.

During Urology Week all activities are organised to explain urology is truly about. We aim to start relevant discussions, inform the lay public about symptoms and treatments, introduce new technologies and insights, and share experiences. It is the ideal opportunity to educate people e.g. to regularly check their bodies for symptoms. Prevention is better than cure. Prevention can save lives.

Every year, Urology Week engages thousands of participants. Whether you’re a urologist, a nurse, a patient or a supporter of this important initiative, we encourage you to join Urology Week, which takes place yearly in the last week of September.

Check out the Urology Week website for tips, helpful material and example of awareness campaigns to spread the word about the importance of urological health.

EPAD

The European Prostate Cancer Awareness Day (EPAD) aims to raise awareness, understanding and knowledge of the management of prostate diseases in general and prostate cancer in particular. By joining forces during a yearly event organised by the EAU, key policy makers, scientific associations and European patient groups review and discuss how to change the management of prostate cancer across Europe to provide a more holistic and personalised tailored care for patients.

In close conjunction with medical experts, representatives from related medical societies and patient advocacy groups, a whitepaper was prepared to lower the risk and mortality rate of Prostate Cancer. This document written for EU politicians provides general information on PCa, highlights the key challenges in improving patient outcomes, and identifies what can be done at European level.

Following the first whitepaper, the European Association of Urology (EAU) launched a second Policy Paper in January 2019 addressing the need to reconsider structured population-based PSA screening for prostate cancer. covering key topics such as the latest evidence, consequences of not performing PSA screening, overdiagnosis & overtreatment, and six recommendations as a call to action:

  • The 2003 Council Recommendations on population-based screening need to be urgently reviewed, with prostate cancer added to the list of cancers to be addressed.
  • Member States should already support a policy update on prostate cancer screening through their work on the EU Joint Action, the Innovative Partnership for Action Against Cancer (IPAAC)
  • MEPs should ensure that European action on Prostate Cancer screening is included in the group manifestos as they prepare for Europe elections
  • The new college of Commissioners mandated in 2019 should be empowered by the European Parliament and Member States to support Member States with European guidelines on prostate cancer screening.
  • Member States should bring good practice on prostate cancer screening to the Steering Group on Health Promotion, Disease Prevention and Management of non-communicable diseases.
  • European Commission encouraged to channel more support and funding to Prostate Cancer screening and research